The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Low-level laser therapy is a non-invasive treatment for TMJ symptoms that uses light to stimulate cellular activity, and it's ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the ...

Pitolisant hydrochloride is under clinical development by Bioprojet SCR and currently in Phase II for Autism Spectrum Disorder (ASD).

New research reveals how sleep apnea may accelerate brain aging and cognitive decline, with experts sharing crucial insights ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

It is the first prescription medication approved to treat the common sleep disorder. The drug’s maker ... said the approval ...

Sleep apnea – a disorder in which breathing stops and starts during the night – may cause damage to small blood vessels in ...

Discover Honey Singhs battle with bipolar disorder his struggles with paranoia and psychosis and the signs to watch out for ...

“Of importance, if sleep apnea affects the brain health and increases the risk for dementias, then treatment of it can serve ...